TikkunLev Therapeutics

Executive Summary

TikkunLev Therapeutics is a private, preclinical-stage biotechnology company founded in 2016 and headquartered in New York, USA. The company is pioneering a first-in-class precision biologic designed to target and repair failing heart muscle, with the ambitious goal of reversing heart failure. Leveraging groundbreaking stem cell and cardiovascular research from its scientific founder, TikkunLev's approach aims to address the root cause of heart failure by regenerating damaged myocardium. The company operates in the biologics sector and is focused on developing a regenerative medicine therapy that could transform the standard of care for millions of patients suffering from chronic heart failure. Heart failure remains a major global health burden with limited curative options, as existing treatments primarily manage symptoms rather than restore cardiac function. TikkunLev's precision biologic has the potential to fill this therapeutic gap by enabling true tissue repair. As a preclinical entity, the company is currently advancing its lead candidate through early-stage R&D, with plans to initiate IND-enabling studies. Success in these steps could position TikkunLev as a key player in the regenerative cardiovascular space. However, the company faces typical preclinical risks, including manufacturing scalability, safety validation, and securing sufficient funding for clinical development. Given the early stage, conviction remains moderate pending further data and milestones.

Upcoming Catalysts (preview)

• Q4 2026IND Submission for Lead Candidate35% success
• Q3 2026Preclinical Efficacy Data Presentation50% success
• TBDSeries B Financing or Partnership25% success